Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is -56.30% vs 26.75% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is -34.39% vs 261.78% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 108.74% vs 1.50% in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is -48.35% vs 320.68% in Mar 2024
Compare Profit and Loss Results of Shukra Pharma.
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
32.00
450.00
-418.00
-92.89%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
32.00
450.00
-418.00
-92.89%
Expenditure (Ex Depriciation)
Stock Adjustments
-3.00
-24.00
21.00
87.50%
Raw Materials Consumed
11.00
178.00
-167.00
-93.82%
Power & Fuel Cost
0.00
29.00
-29.00
-100.00%
Employee Cost
6.00
74.00
-68.00
-91.89%
Operating Expenses
0.00
45.00
-45.00
-100.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
0.00
16.00
-16.00
-100.00%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
0.00
8.00
-8.00
-100.00%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
19.00
358.00
-339.00
-94.69%
Operating Profit (PBDIT) excl Other Income
12.00
91.00
-79.00
-86.81%
Other Income
4.00
23.00
-19.00
-82.61%
Operating Profit (PBDIT)
16.00
115.00
-99.00
-86.09%
Interest
0.00
12.00
-12.00
-100.00%
Profit before Depriciation and Tax
16.00
103.00
-87.00
-84.47%
Depreciation
3.00
20.00
-17.00
-85.00%
Profit Before Taxation & Exceptional Items
13.00
82.00
-69.00
-84.15%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
13.00
89.00
-76.00
-85.39%
Provision for Tax
3.00
24.00
-21.00
-87.50%
Profit After Tax
9.00
64.00
-55.00
-85.94%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
37.00
340.00
-303.00
-89.12%
Profit Available for appropriations
47.00
404.00
-357.00
-88.37%
Appropriations
47.00
404.00
-357.00
-88.37%
Equity Dividend (%)
1%
75%
-74.00
Earnings Per Share
0.22
22.13
-21.91
-99.01%
Profit And Loss - Net Sales
Net Sales 32.59 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -56.30% vs 26.75% in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 12.73 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -34.39% vs 261.78% in Mar 2024
Profit And Loss - Interest
Interest 0.59 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 108.74% vs 1.50% in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax 9.58 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -48.35% vs 320.68% in Mar 2024






